TY  - JOUR
A1  - Rolfes, Muriel
A1  - Borde, Julika
A1  - Möllenhoff, Kathrin
A1  - Kayali, Mohamad
A1  - Ernst, Corinna
A1  - Gehrig, Andrea
A1  - Sutter, Christian
A1  - Ramser, Juliane
A1  - Niederacher, Dieter
A1  - Horváth, Judit
A1  - Arnold, Norbert
A1  - Meindl, Alfons
A1  - Auber, Bernd
A1  - Rump, Andreas
A1  - Wang-Gohrke, Shan
A1  - Ritter, Julia
A1  - Hentschel, Julia
A1  - Thiele, Holger
A1  - Altmüller, Janine
A1  - Nürnberg, Peter
A1  - Rhiem, Kerstin
A1  - Engel, Christoph
A1  - Wappenschmidt, Barbara
A1  - Schmutzler, Rita K.
A1  - Hahnen, Eric
A1  - Hauke, Jan
T1  - Prevalence of cancer predisposition germline variants in male breast cancer patients: results of the German Consortium for Hereditary Breast and Ovarian Cancer
JF  - Cancers
N2  - Male breast cancer (mBC) is associated with a high prevalence of pathogenic variants (PVs) in the BRCA2 gene; however, data regarding other BC predisposition genes are limited. In this retrospective multicenter study, we investigated the prevalence of PVs in BRCA1/2 and 23 non-BRCA1/2 genes using a sample of 614 patients with mBC, recruited through the centers of the German Consortium for Hereditary Breast and Ovarian Cancer. A high proportion of patients with mBC carried PVs in BRCA2 (23.0%, 142/614) and BRCA1 (4.6%, 28/614). The prevalence of BRCA1/2 PVs was 11.0% in patients with mBC without a family history of breast and/or ovarian cancer. Patients with BRCA1/2 PVs did not show an earlier disease onset than those without. The predominant clinical presentation of tumor phenotypes was estrogen receptor (ER)-positive, progesterone receptor (PR)-positive, and HER2-negative (77.7%); further, 10.2% of the tumors were triple-positive, and 1.2% were triple-negative. No association was found between ER/PR/HER2 status and BRCA1/2 PV occurrence. Comparing the prevalence of protein-truncating variants (PTVs) between patients with mBC and control data (ExAC, n = 27,173) revealed significant associations of PTVs in both BRCA1 and BRCA2 with mBC (BRCA1: OR = 17.04, 95% CI = 10.54–26.82, p < 10\(^{−5}\); BRCA2: OR = 77.71, 95% CI = 58.71–102.33, p < 10\(^{−5}\)). A case-control investigation of 23 non-BRCA1/2 genes in 340 BRCA1/2-negative patients and ExAC controls revealed significant associations of PTVs in CHEK2, PALB2, and ATM with mBC (CHEK2: OR = 3.78, 95% CI = 1.59–7.71, p = 0.002; PALB2: OR = 14.77, 95% CI = 5.02–36.02, p < 10\(^{−5}\); ATM: OR = 3.36, 95% CI = 0.89–8.96, p = 0.04). Overall, our findings support the benefit of multi-gene panel testing in patients with mBC irrespective of their family history, age at disease onset, and tumor phenotype.
KW  - breast neoplasms
KW  - male breast cancer
KW  - breast cancer predisposition genes
KW  - genetic testing
KW  - familial breast cancer
Y1  - 2022
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-281758
SN  - 2072-6694
VL  - 14
IS  - 13
ER  - 
TY  - JOUR
A1  - Dumont, Martine
A1  - Weber-Lassalle, Nana
A1  - Joly-Beauparlant, Charles
A1  - Ernst, Corinna
A1  - Droit, Arnaud
A1  - Feng, Bing-Jian
A1  - Dubois, Stéphane
A1  - Collin-Deschesnes, Annie-Claude
A1  - Soucy, Penny
A1  - Vallée, Maxime
A1  - Fournier, Frédéric
A1  - Lemaçon, Audrey
A1  - Adank, Muriel A.
A1  - Allen, Jamie
A1  - Altmüller, Janine
A1  - Arnold, Norbert
A1  - Ausems, Margreet G. E. M.
A1  - Berutti, Riccardo
A1  - Bolla, Manjeet K.
A1  - Bull, Shelley
A1  - Carvalho, Sara
A1  - Cornelissen, Sten
A1  - Dufault, Michael R.
A1  - Dunning, Alison M.
A1  - Engel, Christoph
A1  - Gehrig, Andrea
A1  - Geurts-Giele, Willemina R. R.
A1  - Gieger, Christian
A1  - Green, Jessica
A1  - Hackmann, Karl
A1  - Helmy, Mohamed
A1  - Hentschel, Julia
A1  - Hogervorst, Frans B. L.
A1  - Hollestelle, Antoinette
A1  - Hooning, Maartje J.
A1  - Horváth, Judit
A1  - Ikram, M. Arfan
A1  - Kaulfuß, Silke
A1  - Keeman, Renske
A1  - Kuang, Da
A1  - Luccarini, Craig
A1  - Maier, Wolfgang
A1  - Martens, John W. M.
A1  - Niederacher, Dieter
A1  - Nürnberg, Peter
A1  - Ott, Claus-Eric
A1  - Peters, Annette
A1  - Pharoah, Paul D. P.
A1  - Ramirez, Alfredo
A1  - Ramser, Juliane
A1  - Riedel-Heller, Steffi
A1  - Schmidt, Gunnar
A1  - Shah, Mitul
A1  - Scherer, Martin
A1  - Stäbler, Antje
A1  - Strom, Tim M.
A1  - Sutter, Christian
A1  - Thiele, Holger
A1  - van Asperen, Christi J.
A1  - van der Kolk, Lizet
A1  - van der Luijt, Rob B.
A1  - Volk, Alexander E.
A1  - Wagner, Michael
A1  - Waisfisz, Quinten
A1  - Wang, Qin
A1  - Wang-Gohrke, Shan
A1  - Weber, Bernhard H. F.
A1  - Devilee, Peter
A1  - Tavtigian, Sean
A1  - Bader, Gary D.
A1  - Meindl, Alfons
A1  - Goldgar, David E.
A1  - Andrulis, Irene L.
A1  - Schmutzler, Rita K.
A1  - Easton, Douglas F.
A1  - Schmidt, Marjanka K.
A1  - Hahnen, Eric
A1  - Simard, Jacques
T1  - Uncovering the contribution of moderate-penetrance susceptibility genes to breast cancer by whole-exome sequencing and targeted enrichment sequencing of candidate genes in women of European ancestry
JF  - Cancers
N2  - Rare variants in at least 10 genes, including BRCA1, BRCA2, PALB2, ATM, and CHEK2, are associated with increased risk of breast cancer; however, these variants, in combination with common variants identified through genome-wide association studies, explain only a fraction of the familial aggregation of the disease. To identify further susceptibility genes, we performed a two-stage whole-exome sequencing study. In the discovery stage, samples from 1528 breast cancer cases enriched for breast cancer susceptibility and 3733 geographically matched unaffected controls were sequenced. Using five different filtering and gene prioritization strategies, 198 genes were selected for further validation. These genes, and a panel of 32 known or suspected breast cancer susceptibility genes, were assessed in a validation set of 6211 cases and 6019 controls for their association with risk of breast cancer overall, and by estrogen receptor (ER) disease subtypes, using gene burden tests applied to loss-of-function and rare missense variants. Twenty genes showed nominal evidence of association (p-value < 0.05) with either overall or subtype-specific breast cancer. Our study had the statistical power to detect susceptibility genes with effect sizes similar to ATM, CHEK2, and PALB2, however, it was underpowered to identify genes in which susceptibility variants are rarer or confer smaller effect sizes. Larger sample sizes would be required in order to identify such genes.
KW  - breast cancer
KW  - genetic susceptibility
KW  - whole-exome sequencing
KW  - moderate-penetrance genes
Y1  - 2022
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-281768
SN  - 2072-6694
VL  - 14
IS  - 14
ER  - 
TY  - JOUR
A1  - Sepahi, Ilnaz
A1  - Faust, Ulrike
A1  - Sturm, Marc
A1  - Bosse, Kristin
A1  - Kehrer, Martin
A1  - Heinrich, Tilman
A1  - Grundman-Hauser, Kathrin
A1  - Bauer, Peter
A1  - Ossowski, Stephan
A1  - Susak, Hana
A1  - Varon, Raymonda
A1  - Schröck, Evelin
A1  - Niederacher, Dieter
A1  - Auber, Bernd
A1  - Sutter, Christian
A1  - Arnold, Norbert
A1  - Hahnen, Eric
A1  - Dworniczak, Bernd
A1  - Wang-Gorke, Shan
A1  - Gehrig, Andrea
A1  - Weber, Bernhard H. F.
A1  - Engel, Christoph
A1  - Lemke, Johannes R.
A1  - Hartkopf, Andreas
A1  - Huu Phuc, Nguyen
A1  - Riess, Olaf
A1  - Schroeder, Christopher
T1  - Investigating the effects of additional truncating variants in DNA-repair genes on breast cancer risk in BRCA1-positive women
JF  - BMC Cancer
N2  - Background
Inherited pathogenic variants in BRCA1 and BRCA2 are the most common causes of hereditary breast and ovarian cancer (HBOC). The risk of developing breast cancer by age 80 in women carrying a BRCA1 pathogenic variant is 72%. The lifetime risk varies between families and even within affected individuals of the same family. The cause of this variability is largely unknown, but it is hypothesized that additional genetic factors contribute to differences in age at onset (AAO). Here we investigated whether truncating and rare missense variants in genes of different DNA-repair pathways contribute to this phenomenon.

Methods
We used extreme phenotype sampling to recruit 133 BRCA1-positive patients with either early breast cancer onset, below 35 (early AAO cohort) or cancer-free by age 60 (controls). Next Generation Sequencing (NGS) was used to screen for variants in 311 genes involved in different DNA-repair pathways.

Results
Patients with an early AAO (73 women) had developed breast cancer at a median age of 27 years (interquartile range (IQR); 25.00–27.00 years). A total of 3703 variants were detected in all patients and 43 of those (1.2%) were truncating variants. The truncating variants were found in 26 women of the early AAO group (35.6%; 95%-CI 24.7 - 47.7%) compared to 16 women of controls (26.7%; 95%-CI 16.1 to 39.7%). When adjusted for environmental factors and family history, the odds ratio indicated an increased breast cancer risk for those carrying an additional truncating DNA-repair variant to BRCA1 mutation (OR: 3.1; 95%-CI 0.92 to 11.5; p-value = 0.07), although it did not reach the conventionally acceptable significance level of 0.05.

Conclusions
To our knowledge this is the first time that the combined effect of truncating variants in DNA-repair genes on AAO in patients with hereditary breast cancer is investigated. Our results indicate that co-occurring truncating variants might be associated with an earlier onset of breast cancer in BRCA1-positive patients. Larger cohorts are needed to confirm these results.
KW  - breast cancer
KW  - age at onset
KW  - DNA-repair genes
KW  - next-generation-sequencing
KW  - panel sequencing
KW  - extreme phenotypes
KW  - hereditary breast and ovarian cancer
KW  - BRCA1
KW  - DNA-repair
Y1  - 2019
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-237676
VL  - 19
ER  - 
TY  - JOUR
A1  - Engel, Christoph
A1  - Rhiem, Kerstin
A1  - Hahnen, Eric
A1  - Loibl, Sibylle
A1  - Weber, Karsten E.
A1  - Seiler, Sabine
A1  - Zachariae, Silke
A1  - Hauke, Jan
A1  - Wappenschmidt, Barbara
A1  - Waha, Anke
A1  - Blümcke, Britta
A1  - Kiechle, Marion
A1  - Meindl, Alfons
A1  - Niederacher, Dieter
A1  - Bartram, Claus R.
A1  - Speiser, Dorothee
A1  - Schlegelberger, Brigitte
A1  - Arnold, Norbert
A1  - Wieacker, Peter
A1  - Leinert, Elena
A1  - Gehrig, Andrea
A1  - Briest, Susanne
A1  - Kast, Karin
A1  - Riess, Olaf
A1  - Emons, Günter
A1  - Weber, Bernhard H. F.
A1  - Engel, Jutta
A1  - Schmutzler, Rita K.
T1  - Prevalence of pathogenic BRCA1/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer history
JF  - BMC Cancer
N2  - Background 
There is no international consensus up to which age women with a diagnosis of triple-negative breast cancer (TNBC) and no family history of breast or ovarian cancer should be offered genetic testing for germline BRCA1 and BRCA2 (gBRCA) mutations. Here, we explored the association of age at TNBC diagnosis with the prevalence of pathogenic gBRCA mutations in this patient group. 

Methods
The study comprised 802 women (median age 40 years, range 19-76) with oestrogen receptor, progesterone receptor, and human epidermal growth factor receptor type 2 negative breast cancers, who had no relatives with breast or ovarian cancer. All women were tested for pathogenic gBRCA mutations. Logistic regression analysis was used to explore the association between age at TNBC diagnosis and the presence of a pathogenic gBRCA mutation. 

Results
A total of 127 women with TNBC(15.8%) were gBRCA mutation carriers (BRCA1: n = 118, 14.7%; BRCA2: n = 9, 1. 1%). The mutation prevalence was 32.9% in the age group 20-29 years compared to 6.9% in the age group 60-69 years. Logistic regression analysis revealed a significant increase of mutation frequency with decreasing age at diagnosis (odds ratio 1.87 per 10 year decrease, 95% CI 1.50-2.32, p < 0.001). gBRCA mutation risk was predicted to be > 10% for women diagnosed below approximately 50 years. 

Conclusions
Based on the general understanding that a heterozygous mutation probability of 10% or greater justifies gBRCA mutation screening, women with TNBC diagnosed before the age of 50 years and no familial history of breast and ovarian cancer should be tested for gBRCA mutations. In Germany, this would concern approximately 880 women with newly diagnosed TNBC per year, of whom approximately 150 are expected to be identified as carriers of a pathogenic gBRCA mutation.
KW  - hereditary breast and ovarian cancer
KW  - BRCA1
KW  - BRCA2
KW  - triple-negative breast cancer
Y1  - 2018
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-226763
VL  - 18
ER  - 
TY  - JOUR
A1  - Weber-Lassalle, Nana
A1  - Hauke, Jan
A1  - Ramser, Juliane
A1  - Richters, Lisa
A1  - Groß, Eva
A1  - Blümcke, Britta
A1  - Gehrig, Andrea
A1  - Kahlert, Anne-Karin
A1  - Müller, Clemens R.
A1  - Hackmann, Karl
A1  - Honisch, Ellen
A1  - Weber-Lassalle, Konstantin
A1  - Niederacher, Dieter
A1  - Borde, Julika
A1  - Thiele, Holger
A1  - Ernst, Corinna
A1  - Altmüller, Janine
A1  - Neidhardt, Guido
A1  - Nürnberg, Peter
A1  - Klaschik, Kristina
A1  - Schroeder, Christopher
A1  - Platzer, Konrad
A1  - Volk, Alexander E.
A1  - Wang-Gohrke, Shan
A1  - Just, Walter
A1  - Auber, Bernd
A1  - Kubisch, Christian
A1  - Schmidt, Gunnar
A1  - Horvath, Judit
A1  - Wappenschmidt, Barbara
A1  - Engel, Christoph
A1  - Arnold, Norbert
A1  - Dworniczak, Bernd
A1  - Rhiem, Kerstin
A1  - Meindl, Alfons
A1  - Schmutzler, Rita K.
A1  - Hahnen, Eric
T1  - BRIP1 loss-of-function mutations confer high risk for familial ovarian cancer, but not familial breast cancer
JF  - Breast Cancer Research
N2  - Background
Germline mutations in the BRIP1 gene have been described as conferring a moderate risk for ovarian cancer (OC), while the role of BRIP1 in breast cancer (BC) pathogenesis remains controversial.

Methods
To assess the role of deleterious BRIP1 germline mutations in BC/OC predisposition, 6341 well-characterized index patients with BC, 706 index patients with OC, and 2189 geographically matched female controls were screened for loss-of-function (LoF) mutations and potentially damaging missense variants. All index patients met the inclusion criteria of the German Consortium for Hereditary Breast and Ovarian Cancer for germline testing and tested negative for pathogenic BRCA1/2 variants.

Results
BRIP1 LoF mutations confer a high OC risk in familial index patients (odds ratio (OR) = 20.97, 95% confidence interval (CI) = 12.02–36.57, P < 0.0001) and in the subgroup of index patients with late-onset OC (OR = 29.91, 95% CI = 14.99–59.66, P < 0.0001). No significant association of BRIP1 LoF mutations with familial BC was observed (OR = 1.81 95% CI = 1.00–3.30, P = 0.0623). In the subgroup of familial BC index patients without a family history of OC there was also no apparent association (OR = 1.42, 95% CI = 0.70–2.90, P = 0.3030). In 1027 familial BC index patients with a family history of OC, the BRIP1 mutation prevalence was significantly higher than that observed in controls (OR = 3.59, 95% CI = 1.43–9.01; P = 0.0168). Based on the negative association between BRIP1 LoF mutations and familial BC in the absence of an OC family history, we conclude that the elevated mutation prevalence in the latter cohort was driven by the occurrence of OC in these families. Compared with controls, predicted damaging rare missense variants were significantly more prevalent in OC (P = 0.0014) but not in BC (P = 0.0693) patients.

Conclusions
To avoid ambiguous results, studies aimed at assessing the impact of candidate predisposition gene mutations on BC risk might differentiate between BC index patients with an OC family history and those without. In familial cases, we suggest that BRIP1 is a high-risk gene for late-onset OC but not a BC predisposition gene, though minor effects cannot be excluded.
KW  - breast cancer
KW  - ovarian cancer
KW  - BRIP1 gene
KW  - germline mutations
Y1  - 2018
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-233433
VL  - 20
ER  - 
TY  - JOUR
A1  - Harter, Philipp
A1  - Hauke, Jan
A1  - Heitz, Florian
A1  - Reuss, Alexander
A1  - Kommoss, Stefan
A1  - Marmé, Frederik
A1  - Heimbach, André
A1  - Prieske, Katharina
A1  - Richters, Lisa
A1  - Burges, Alexander
A1  - Neidhardt, Guido
A1  - de Gregorio, Nikolaus
A1  - El-Balat, Ahmed
A1  - Hilpert, Felix
A1  - Meier, Werner
A1  - Kimmig, Rainer
A1  - Kast, Karin
A1  - Sehouli, Jalid
A1  - Baumann, Klaus
A1  - Jackisch, Christian
A1  - Park-Simon, Tjoung-Won
A1  - Hanker, Lars
A1  - Kröber, Sandra
A1  - Pfisterer, Jacobus
A1  - Gevensleben, Heidrun
A1  - Schnelzer, Andreas
A1  - Dietrich, Dimo
A1  - Neunhöffer, Tanja
A1  - Krockenberger, Mathias
A1  - Brucker, Sara Y.
A1  - Nürnberg, Peter
A1  - Thiele, Holger
A1  - Altmüller, Janine
A1  - Lamla, Josefin
A1  - Elser, Gabriele
A1  - du Bois, Andreas
A1  - Hahnen, Eric
A1  - Schmutzler, Rita
T1  - Prevalence of deleterious germline variants in risk genes including \(BRCA1/2\) in consecutive ovarian cancer patients (AGO-TR-1)
JF  - PLoS ONE
N2  - Background
Identification of families at risk for ovarian cancer offers the opportunity to consider prophylactic surgery thus reducing ovarian cancer mortality. So far, identification of potentially affected families in Germany was solely performed via family history and numbers of affected family members with breast or ovarian cancer. However, neither the prevalence of deleterious variants in \(BRCA1/2\) in ovarian cancer in Germany nor the reliability of family history as trigger for genetic counselling has ever been evaluated.

Methods
Prospective counseling and germline testing of consecutive patients with primary diagnosis or with platinum-sensitive relapse of an invasive epithelial ovarian cancer. Testing included 25 candidate and established risk genes. Among these 25 genes, 16 genes (\(ATM\), \(BRCA1\), \(BRCA2\), \(CDH1\), \(CHEK2\), \(MLH1\), \(MSH2\), \(MSH6\), \(NBN\), \(PMS2\), \(PTEN\), \(PALB2\), \(RAD51C\), \(RAD51D\), \(STK11\), \(TP53\)) were defined as established cancer risk genes. A positive family history was defined as at least one relative with breast cancer or ovarian cancer or breast cancer in personal history.

Results
In total, we analyzed 523 patients: 281 patients with primary diagnosis of ovarian cancer and 242 patients with relapsed disease. Median age at primary diagnosis was 58 years (range 16–93) and 406 patients (77.6%) had a high-grade serous ovarian cancer. In total, 27.9% of the patients showed at least one deleterious variant in all 25 investigated genes and 26.4% in the defined 16 risk genes. Deleterious variants were most prevalent in the \(BRCA1\) (15.5%), \(BRCA2\) (5.5%), \(RAD51C\) (2.5%) and \(PALB2\) (1.1%) genes. The prevalence of deleterious variants did not differ significantly between patients at primary diagnosis and relapse. The prevalence of deleterious variants in \(BRCA1/2\) (and in all 16 risk genes) in patients <60 years was 30.2% (33.2%) versus 10.6% (18.9%) in patients \(\geq\)60 years. Family history was positive in 43% of all patients. Patients with a positive family history had a prevalence of deleterious variants of 31.6% (36.0%) versus 11.4% (17.6%) and histologic subtype of high grade serous ovarian cancer versus other showed a prevalence of deleterious variants of 23.2% (29.1%) and 10.2% (14.8%), respectively. Testing only for \(BRCA1/2\) would miss in our series more than 5% of the patients with a deleterious variant in established risk genes.

Conclusions
26.4% of all patients harbor at least one deleterious variant in established risk genes. The threshold of 10% mutation rate which is accepted for reimbursement by health care providers in Germany was observed in all subgroups analyzed and neither age at primary diagnosis nor histo-type or family history sufficiently enough could identify a subgroup not eligible for genetic counselling and testing. Genetic testing should therefore be offered to every patient with invasive epithelial ovarian cancer and limiting testing to \(BRCA1/2\) seems to be
not sufficient.
KW  - medicine
KW  - Genetic causes of cancer
KW  - ovarian cancer
KW  - cancer risk factors
KW  - histology
KW  - cancer detection and diagnosis
KW  - breast cancer
KW  - genetic testing
KW  - human genetics
Y1  - 2017
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-173553
VL  - 12
IS  - 10
ER  - 
TY  - JOUR
A1  - Silvestri, Valentina
A1  - Barrowdale, Daniel
A1  - Mulligan, Anna Marie
A1  - Neuhausen, Susan L.
A1  - Fox, Stephen
A1  - Karlan, Beth Y.
A1  - Mitchell, Gillian
A1  - James, Paul
A1  - Thull, Darcy L.
A1  - Zorn, Kristin K.
A1  - Carter, Natalie J.
A1  - Nathanson, Katherine L.
A1  - Domchek, Susan M.
A1  - Rebbeck, Timothy R.
A1  - Ramus, Susan J.
A1  - Nussbaum, Robert L.
A1  - Olopade, Olufunmilayo I.
A1  - Rantala, Johanna
A1  - Yoon, Sook-Yee
A1  - Caligo, Maria A.
A1  - Spugnesi, Laura
A1  - Bojesen, Anders
A1  - Pedersen, Inge Sokilde
A1  - Thomassen, Mads
A1  - Jensen, Uffe Birk
A1  - Toland, Amanda Ewart
A1  - Senter, Leigha
A1  - Andrulis, Irene L.
A1  - Glendon, Gord
A1  - Hulick, Peter J.
A1  - Imyanitov, Evgeny N.
A1  - Greene, Mark H.
A1  - Mai, Phuong L.
A1  - Singer, Christian F.
A1  - Rappaport-Fuerhauser, Christine
A1  - Kramer, Gero
A1  - Vijai, Joseph
A1  - Offit, Kenneth
A1  - Robson, Mark
A1  - Lincoln, Anne
A1  - Jacobs, Lauren
A1  - Machackova, Eva
A1  - Foretova, Lenka
A1  - Navratilova, Marie
A1  - Vasickova, Petra
A1  - Couch, Fergus J.
A1  - Hallberg, Emily
A1  - Ruddy, Kathryn J.
A1  - Sharma, Priyanka
A1  - Kim, Sung-Won
A1  - Teixeira, Manuel R.
A1  - Pinto, Pedro
A1  - Montagna, Marco
A1  - Matricardi, Laura
A1  - Arason, Adalgeir
A1  - Johannsson, Oskar Th
A1  - Barkardottir, Rosa B.
A1  - Jakubowska, Anna
A1  - Lubinski, Jan
A1  - Izquierdo, Angel
A1  - Pujana, Miguel Angel
A1  - Balmaña, Judith
A1  - Diez, Orland
A1  - Ivady, Gabriella
A1  - Papp, Janos
A1  - Olah, Edith
A1  - Kwong, Ava
A1  - Nevanlinna, Heli
A1  - Aittomäki, Kristiina
A1  - Segura, Pedro Perez
A1  - Caldes, Trinidad
A1  - Van Maerken, Tom
A1  - Poppe, Bruce
A1  - Claes, Kathleen B. M.
A1  - Isaacs, Claudine
A1  - Elan, Camille
A1  - Lasset, Christine
A1  - Stoppa-Lyonnet, Dominique
A1  - Barjhoux, Laure
A1  - Belotti, Muriel
A1  - Meindl, Alfons
A1  - Gehrig, Andrea
A1  - Sutter, Christian
A1  - Engel, Christoph
A1  - Niederacher, Dieter
A1  - Steinemann, Doris
A1  - Hahnen, Eric
A1  - Kast, Karin
A1  - Arnold, Norbert
A1  - Varon-Mateeva, Raymonda
A1  - Wand, Dorothea
A1  - Godwin, Andrew K.
A1  - Evans, D. Gareth
A1  - Frost, Debra
A1  - Perkins, Jo
A1  - Adlard, Julian
A1  - Izatt, Louise
A1  - Platte, Radka
A1  - Eeles, Ros
A1  - Ellis, Steve
A1  - Hamann, Ute
A1  - Garber, Judy
A1  - Fostira, Florentia
A1  - Fountzilas, George
A1  - Pasini, Barbara
A1  - Giannini, Giuseppe
A1  - Rizzolo, Piera
A1  - Russo, Antonio
A1  - Cortesi, Laura
A1  - Papi, Laura
A1  - Varesco, Liliana
A1  - Palli, Domenico
A1  - Zanna, Ines
A1  - Savarese, Antonella
A1  - Radice, Paolo
A1  - Manoukian, Siranoush
A1  - Peissel, Bernard
A1  - Barile, Monica
A1  - Bonanni, Bernardo
A1  - Viel, Alessandra
A1  - Pensotti, Valeria
A1  - Tommasi, Stefania
A1  - Peterlongo, Paolo
A1  - Weitzel, Jeffrey N.
A1  - Osorio, Ana
A1  - Benitez, Javier
A1  - McGuffog, Lesley
A1  - Healey, Sue
A1  - Gerdes, Anne-Marie
A1  - Ejlertsen, Bent
A1  - Hansen, Thomas V. O.
A1  - Steele, Linda
A1  - Ding, Yuan Chun
A1  - Tung, Nadine
A1  - Janavicius, Ramunas
A1  - Goldgar, David E.
A1  - Buys, Saundra S.
A1  - Daly, Mary B.
A1  - Bane, Anita
A1  - Terry, Mary Beth
A1  - John, Esther M.
A1  - Southey, Melissa
A1  - Easton, Douglas F.
A1  - Chenevix-Trench, Georgia
A1  - Antoniou, Antonis C.
A1  - Ottini, Laura
T1  - Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2
JF  - Breast Cancer Research
N2  - Background

BRCA1 and, more commonly, BRCA2 mutations are associated with increased risk of male breast cancer (MBC). However, only a paucity of data exists on the pathology of breast cancers (BCs) in men with BRCA1/2 mutations. Using the largest available dataset, we determined whether MBCs arising in BRCA1/2 mutation carriers display specific pathologic features and whether these features differ from those of BRCA1/2 female BCs (FBCs).

Methods

We characterised the pathologic features of 419 BRCA1/2 MBCs and, using logistic regression analysis, contrasted those with data from 9675 BRCA1/2 FBCs and with population-based data from 6351 MBCs in the Surveillance, Epidemiology, and End Results (SEER) database.

Results

Among BRCA2 MBCs, grade significantly decreased with increasing age at diagnosis (P = 0.005). Compared with BRCA2 FBCs, BRCA2 MBCs were of significantly higher stage (P for trend = 2 × 10−5) and higher grade (P for trend = 0.005) and were more likely to be oestrogen receptor–positive [odds ratio (OR) 10.59; 95 % confidence interval (CI) 5.15–21.80] and progesterone receptor–positive (OR 5.04; 95 % CI 3.17–8.04). With the exception of grade, similar patterns of associations emerged when we compared BRCA1 MBCs and FBCs. BRCA2 MBCs also presented with higher grade than MBCs from the SEER database (P for trend = 4 × 10−12).

Conclusions

On the basis of the largest series analysed to date, our results show that BRCA1/2 MBCs display distinct pathologic characteristics compared with BRCA1/2 FBCs, and we identified a specific BRCA2-associated MBC phenotype characterised by a variable suggesting greater biological aggressiveness (i.e., high histologic grade). These findings could lead to the development of gender-specific risk prediction models and guide clinical strategies appropriate for MBC management.
KW  - Male breast cancer
KW  - BRCA1/2
KW  - Pathology
KW  - Histologic grade
KW  - Genotype–phenotype correlations
Y1  - 2016
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-164769
VL  - 18
IS  - 15
ER  -